Literature DB >> 19891528

Thrombopoietic cytokines and platelet count in multiple myeloma.

Zübeyde Nur Ozkurt1, Münci Yağci, Gülsan Türköz Sucak, Serafettin Kirazli, Rauf Haznedar.   

Abstract

Cytokines like interleukin (IL)-6 and IL-1beta are both implicated in multiple myeloma (MM) pathogenesis and megakaryopoiesis. The dynamic interaction between thrombopoiesis and thrombopoietic cytokines in MM may affect platelet (PLT) counts. Sixty-eight patients with MM (30 female, 38 male; median age 58 (40-79), 38 newly diagnosed, 15 in plateau, and 15 relapse and/or refractory patients) and 21 controls were included in the study. Plasma levels of thrombopoietin (TPO), IL-1beta, IL-11 and IL-6 were measured by ELISA. PLT counts were not different between the control group and MM patients with various disease stages and activity. IL-6 and TPO levels were higher in MM patients than healthy subjects (p < 0.001). PLT counts were inversely correlated with TPO (r = -0.566; p < 0.001) and positively correlated with IL-6 (r = 0.263; p = 0.04) levels in MM patients. TPO and IL-6 levels were significantly correlated (r = 0.305; p < 0.001). Disease activity has no effect on plasma cytokine levels. TPO levels were higher in stage III than stage I (p = 0.05) and stage II (p = 0.03) patients in newly diagnosed MM. High TPO levels induced by IL-6 may sustain normal PLT counts despite bone marrow infiltration by plasma cells and decreased PLT half-life.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19891528     DOI: 10.3109/09537100903360007

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  6 in total

1.  Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients.

Authors:  Aneta Szudy-Szczyrek; Radosław Mlak; Michał Szczyrek; Sylwia Chocholska; Jacek Sompor; Adam Nogalski; Teresa Małecka-Massalska; Marek Hus
Journal:  Oncotarget       Date:  2018-05-08

2.  Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma?

Authors:  Serife Solmaz; Ozcan Uzun; Celal Acar; Omur Gokmen Sevindik; Ozden Piskin; Hayri Guner Ozsan; Fatih Demirkan; Bulent Undar; Ahmet Alacacioglu; Mehmet Ali Ozcan; Inci Alacacioglu
Journal:  J Lab Physicians       Date:  2018 Oct-Dec

3.  SARS-CoV-2 infection associated with monoclonal gammopathy. A case report based on the study of minimally invasive ultrasound-guided autopsy.

Authors:  María Del Carmen González-García; Pablo Pérez Montero; Eva Manuela Pena Burgos; Cristina Vega Cabrera; Teresa Hernández Cabrero; Begoña Rivas Becerra; Laura Yébenes; David Hardisson
Journal:  Rev Esp Patol       Date:  2021-10-13

4.  Dysmegakaryocytopoiesis and maintaining platelet count in patients with plasma cell neoplasm.

Authors:  Yasmin Mair; Yan Zheng; Donghong Cai
Journal:  N Am J Med Sci       Date:  2013-05

5.  Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment.

Authors:  Sung-Hoon Jung; Jae-Sook Ahn; Deok-Hwan Yang; Min-Seok Cho; Jae-Yong Kim; Seo-Yeon Ahn; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Blood Res       Date:  2015-09-22

6.  Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma.

Authors:  Ga-Young Song; Sung-Hoon Jung; Kihyun Kim; Seok Jin Kim; Sang Eun Yoon; Ho Sup Lee; Mihee Kim; Seo-Yeon Ahn; Jae-Sook Ahn; Deok-Hwan Yang; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  BMC Cancer       Date:  2020-08-24       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.